Compare BridgeBio Pharma Inc (BBIO) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nu Holdings Ltd — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Nu Holdings Ltd trades at $14.06 (market cap $66.03B). The key difference: Nu Holdings Ltd is far larger — about 4.1× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | NU | |
|---|---|---|
Market Cap | $16.27B | $66.03B |
Sector | Health | Financials |
52-Week High | $90.17 | $18.76 |
52-Week Low | $44.81 | $11.60 |
Enterprise Value | $17.82B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NU Holdings trades at $13.67, down 0.65% on the day, with strong fundamental performance including 26.72% net income margin and 30.04% ROE. The company shows impressive revenue growth from $3.0B in 2022 to $10.63B in 2025, with technical indicators showing a bullish trend supported by moving averages. Recent approval for banking operations in Mexico with 15 million customers provides significant growth catalyst.
NU presents a compelling growth story with expanding profitability and Latin American market penetration. The stock trades below analyst consensus target of $14.98, offering potential upside, though currency headwinds and credit risks in emerging markets remain concerns. With 54.55% analyst buy ratings and strong cash flow generation, the long-term outlook appears positive despite recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
